<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695877</url>
  </required_header>
  <id_info>
    <org_study_id>Ad5HVR48.ENVA.01/IPCAVD-002</org_study_id>
    <secondary_id>10701</secondary_id>
    <secondary_id>Ad5HVR48.ENVA.01/ IPCAVD-002</secondary_id>
    <nct_id>NCT00695877</nct_id>
  </id_info>
  <brief_title>Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults</brief_title>
  <official_title>A Phase I Randomized, Double-blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 5 HVR48 HIV-1 Vaccine (Ad5HVR48.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad5HVR48.ENVA.01 (rAd5HVR48) HIV-1/IPCAVD-002 Vaccine Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Successful control of the HIV epidemic will require a safe and effective vaccine to be&#xD;
      developed. A successful vaccine will need to stimulate a widespread immune response. The&#xD;
      purpose of this study is to determine the safety of and immune response to an adenovirus&#xD;
      serotype HIV vaccine in HIV uninfected adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Control of the HIV pandemic can only be achieved with the development of a safe and effective&#xD;
      preventive HIV vaccine. A vaccine that will prevent HIV infection will elicit a strong immune&#xD;
      response from both CD4 and CD8 cells. Recombinant adenovirus serotype vectors have been shown&#xD;
      to elicit just such a response. The purpose of this study is to determine the safety and&#xD;
      immunogenicity of the recombinant adenovirus serotype 5 preventive HIV-1 vaccine.&#xD;
&#xD;
      This study will last 18 to 24 months. Participants will be randomly assigned to one of four&#xD;
      arms that will receive vaccine or placebo administered via intramuscular injection.&#xD;
      Participants in Arms 1, 2, and 3 will all receive 3 injections. Participants in Arm 4 will&#xD;
      receive one injection. For most participants, there will be 10 study visits in this study;&#xD;
      for participants in Arm 4, there will be only 7 visits. For Arms 1, 2, and 3, study visits&#xD;
      will occur at baseline and on Days 0, 14, 28, 42, 56, 168, 182,196, and 365. Participants in&#xD;
      Arms 1, 2, and 3 will receive injections on Days 0, 28, and 168. For participants in Arm 4,&#xD;
      study visits will occur at baseline and on Days 0, 14, 28, 56, 168 and 365. Participants in&#xD;
      Arm 4 will receive one injection only, on Day 0. Participants will be asked to record their&#xD;
      temperature and other side effects in a symptom log for 3 days after each injection. Risk&#xD;
      reduction/pregnancy prevention counseling and physical exams will occur at all visits. At&#xD;
      most visits, blood, urine, and oral swab collection will occur. Samples collected will be&#xD;
      stored for future testing. HIV testing and pregnancy testing will occur at select visits. At&#xD;
      Years 2, 3, 4, and 5, participants will be followed-up by telephone, e-mail, or study visit&#xD;
      to collect vital status, and information about any development of significant disability or&#xD;
      incapacity, hospitalizations, or congenital anomalies. At these follow-up visits, blood&#xD;
      collection will be optional.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2009</start_date>
  <completion_date type="Actual">October 14, 2016</completion_date>
  <primary_completion_date type="Actual">December 11, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local and systemic adverse reactions</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral Immune response</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell mediated immunity</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^10 virus particles (VP) given at Days 0, 28, and 168</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^11 virus particles (VP) given at Days 0, 28, and 168</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 injection of rAd5.ENVA.48 HIV-1 vaccine or placebo at a dose determined by the safety data from Arms 1, 2 and 3 given at Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5.ENVA.48 HIV-1 vaccine</intervention_name>
    <description>Recombinant adenovirus serotype 5 HIV-1 vaccine</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  Normal hematological, hepatic and renal functions&#xD;
&#xD;
          -  Demonstrated understanding of study&#xD;
&#xD;
          -  Willing to receive HIV test results&#xD;
&#xD;
          -  HIV-1 and -2 uninfected&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Anti-hepatitis C virus (anti-HCV) negative antibody or negative HCV PCR if anti-HCV is&#xD;
             positive&#xD;
&#xD;
          -  Adequate contraception. For more information on this criterion can be found in the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV vaccines or placebos in prior HIV vaccine trial&#xD;
&#xD;
          -  Immunosuppressive medications within 168 days prior to first injection. Participants&#xD;
             taking corticosteroid nasal spray or topical corticosteroids are not excluded.&#xD;
&#xD;
          -  Blood products within 120 days prior to first injection&#xD;
&#xD;
          -  Immunoglobulin within 60 days prior to first injection&#xD;
&#xD;
          -  Investigational agents within 30 days prior to first injections&#xD;
&#xD;
          -  Live attenuated vaccine within 30 days prior to first injection&#xD;
&#xD;
          -  Any vaccine that is not a live attenuated vaccine within 14 days prior to first&#xD;
             injection&#xD;
&#xD;
          -  Any clinically significant medical condition that, in the opinion of the investigator,&#xD;
             may interfere with the study&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or social condition or responsibility that, in&#xD;
             the opinion of the investigator, would interfere with the study&#xD;
&#xD;
          -  Serious adverse reaction to vaccines. Participants who had a nonanaphylactic adverse&#xD;
             reaction to pertussis vaccine as a child are not excluded.&#xD;
&#xD;
          -  Known autoimmune disease&#xD;
&#xD;
          -  Known immunodeficiency&#xD;
&#xD;
          -  Asthma other than mild, well-controlled asthma&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2&#xD;
&#xD;
          -  Thyroidectomy or thyroid disease in the12 months prior to study entry&#xD;
&#xD;
          -  Angioedema in the 3 years prior to study entry&#xD;
&#xD;
          -  Hypertension. More information on this criterion can be found in the protocol.&#xD;
&#xD;
          -  Body mass index (BMI) of 40 or higher OR BMI of 35 or greater, if other cardiovascular&#xD;
             risk factors. More information on this criterion can be found in the protocol.&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Malignancy, unless it has been surgically removed and, in the opinion of the&#xD;
             investigator, is not likely to recur during the study period&#xD;
&#xD;
          -  Seizure disorder or occurrence of seizure in the 3 years prior to study entry.&#xD;
             Participants who have not required medications or had a seizure for prior 3 years are&#xD;
             not excluded.&#xD;
&#xD;
          -  Absence of spleen&#xD;
&#xD;
          -  Individuals at high-risk of acquiring HIV infection&#xD;
&#xD;
          -  Presence of pre-existing neutralizing antibodies for Adenovirus 5 or 48&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Baden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Barouch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. Novel Adenoviral Vector Prophylactic HIV Vaccine Non-Network CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.</citation>
    <PMID>18433307</PMID>
  </reference>
  <reference>
    <citation>Stevens W, Kamali A, Karita E, Anzala O, Sanders EJ, Jaoko W, Kaleebu P, Mulenga J, Dally L, Fast P, Gilmour J, Farah B, Birungi J, Hughes P, Manigart O, Stevens G, Yates S, Thomson H, von Lieven A, Krebs M, Price MA, Stoll-Johnson L, Ketter N. Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One. 2008 Apr 30;3(4):e2043. doi: 10.1371/journal.pone.0002043.</citation>
    <PMID>18446196</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

